Bristol-Myers Squibb (NYSE: BMY) reported earnings on July 25. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 30 (Q2), Bristol-Myers Squibb met expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue shrank. Non-GAAP earnings per share contracted. GAAP earnings per share dropped significantly.

Margins dropped across the board.

Revenue details
Bristol-Myers Squibb chalked up revenue of $4.05 billion. The 14 analysts polled by S&P Capital IQ hoped for revenue of $4.05 billion on the same basis. GAAP reported sales were 8.9% lower than the prior-year quarter's $4.44 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.44. The 17 earnings estimates compiled by S&P Capital IQ predicted $0.44 per share. Non-GAAP EPS of $0.44 for Q2 were 8.3% lower than the prior-year quarter's $0.48 per share. GAAP EPS of $0.32 for Q2 were 16% lower than the prior-year quarter's $0.38 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 72.6%, 270 basis points worse than the prior-year quarter. Operating margin was 18.0%, 910 basis points worse than the prior-year quarter. Net margin was 13.2%, 130 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
Next quarter's average estimate for revenue is $4.05 billion. On the bottom line, the average EPS estimate is $0.46.

Next year's average estimate for revenue is $16.34 billion. The average EPS estimate is $1.80.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,660 members out of 1,773 rating the stock outperform, and 113 members rating it underperform. Among 485 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 466 give Bristol-Myers Squibb a green thumbs-up, and 19 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bristol-Myers Squibb is outperform, with an average price target of $46.25.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Bristol-Myers Squibb. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.